MONICA CHEN to Protein Kinase Inhibitors
This is a "connection" page, showing publications MONICA CHEN has written about Protein Kinase Inhibitors.
Connection Strength
0.756
-
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol. 2025 Oct; 26(10):1357-1369.
Score: 0.164
-
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets. Clin Cancer Res. 2024 Sep 03; 30(17):3812-3823.
Score: 0.153
-
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors. Cancer Discov. 2024 Aug 02; 14(8):1440-1456.
Score: 0.152
-
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 04; 8:e2300454.
Score: 0.148
-
Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors. JCO Precis Oncol. 2023 05; 7:e2200697.
Score: 0.139